Product Details
| Product Name:
Ergolide |
CAS No.:
54999-07-4 |
| Purity:
99.56% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | Ergolide |
| Description | Ergolide, a sesquiterpene lactone extracted from the dried flowers of Inula Britannica, effectively hinders the expression of inducible nitric oxide synthase and cyclo-oxygenase-2 in RAW 264.7 macrophages by deactivating NF-κB. |
| In vitro | Ergolide markedly decreased the production of prostaglandin E(2) (PGE(2)) in cell-free extract of LPS/IFN-gamma-stimulated RAW 264.7 macrophages in a concentration-dependent manner, without alteration of the catalytic activity of COX-2 itself.?Ergolide decreased the level of iNOS and COX-2 protein, and iNOS mRNA caused by stimulation of LPS/IFN-gamma in a concentration-dependent manner, as measured by Western blot and Northern blot analysis, respectively.?Ergolide inhibited nuclear factor-kappaB (NF-kappaB) activation, a transcription factor necessary for iNOS and COX-2 expression in response to LPS/IFN-gamma.?This effect was accompanied by the parallel reduction of nuclear translocation of subunit p65 of NF-kappaB as well as IkappaB-alpha degradation.?In addition, these effects were completely blocked by treatment of cysteine, indicating that this inhibitory effect of ergolide could be mediated by alkylation of NF-kappaB itself or an upstream molecule of NF-kappaB.?Ergolide also directly inhibited the DNA-binding activity of active NF-kappaB in LPS/IFN-gamma-pretreated RAW 264.7 macrophages.?These results demonstrate that the suppression of NF-kappaB activation by ergolide might be attributed to the inhibition of nuclear translocation of NF-kappaB resulted from blockade of the degradation of IkappaB and the direct modification of active NF-kappaB, leading to the suppression of the expression of iNOS and COX-2,?which play important roles in inflammatory signalling pathway. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (163.21 mM), Sonication is recommended.
|
| Keywords | Nuclear factor-kappaB | Nuclear factor-κB | Inhibitor | Ergolide | NF-κB | inhibit |
| Inhibitors Related | Sodium Houttuyfonate | Zingerone | Lidocaine | Diethylmaleate | Glucosamine | sodium lauroyl-α-hydroxyethyl sulfonate | Lidocaine hydrochloride | 5-Aminosalicylic Acid | Indole-3-carbinol | Diallyl disulfide | Caffeic Acid Phenethyl Ester | Sodium salicylate |
| Related Compound Libraries | Anti-Tumor Natural Product Library | Terpene Natural Product Library | Anti-Inflammatory Traditional Chinese Medicine Compound Library | Natural Product Library | Inhibitor Library | Natural Product Library for HTS | Anti-Aging Compound Library | Bioactive Compounds Library Max | Ancient Chinese Classical Formulas Compound Library | Food as Medicine Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:188260-50-6
$2500.00 / 100mg
-
CAS:1142214-62-7
$1160.00 / 50mg
-
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$68.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States